In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci.
about
Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureusActivity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalisCharacterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptidesEfficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditisIn vitro activity of the new glycopeptide LY333328 against multiply resistant gram-positive clinical isolates.Comparison of inhibitory and bactericidal activities and postantibiotic effects of LY333328 and ampicillin used singly and in combination against vancomycin-resistant Enterococcus faecium.Vancomycin-resistant enterococci.Synergy of an investigational glycopeptide, LY333328, with once-daily gentamicin against vancomycin-resistant Enterococcus faecium in a multiple-dose, in vitro pharmacodynamic modelAntimicrobial susceptibility patterns of enterococci causing infections in Europe. The European VRE Study Group.In vitro activities of LY333328 and comparative agents against nosocomial gram-positive pathogens collected in a 1997 global surveillance study.Experimental study of LY333328 (oritavancin), alone and in combination, in therapy of cephalosporin-resistant pneumococcal meningitisOritavancin for acute bacterial skin and skin structure infections.Fecal carriage of vancomycin-resistant enterococci in hospitalized patients and those living in the community in The Netherlands.Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: study of antibiotic combinationsOritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia.
P2860
Q24556635-DBB3AB9A-D8F9-49E5-B7E6-F4E7EC222EE4Q33594048-3E9DB923-888B-44A0-95CB-58996F744626Q33661713-BCFF3E87-4743-41FD-B729-347F8987BD63Q33693084-4E372855-AEC7-4F67-820F-27F7A0118FBEQ33697465-5F230B1C-2A1A-4032-8680-82B4BC958F69Q33698979-A8C18BCD-E00E-451C-853E-50250AE9AF9BQ33975592-3A063CCF-8263-4C7E-AAF2-A80CB6224191Q33976444-075AB1FE-C43D-4D01-A971-A9361FDFF5D6Q33977918-3F476D2E-993B-4137-AB78-258155A17086Q33979559-A0B60841-98EE-4E65-9CC0-D7F2C3F70957Q35013994-62A78269-A484-495D-AD20-0C6087DECC5BQ36086423-2E5CDDA9-AAD5-4560-BF76-2230A32CBF46Q36547828-7391A999-990E-4234-A377-11C387CA2184Q37144883-FADFD5E0-39C3-4C5A-A02E-F77AB8066441Q37392932-F9445E3F-B638-47AE-BE3A-F7C5AACC3995
P2860
In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci.
description
1996 nî lūn-bûn
@nan
1996 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
In vitro activity of LY333328, ...... enterococci and staphylococci.
@ast
In vitro activity of LY333328, ...... enterococci and staphylococci.
@en
type
label
In vitro activity of LY333328, ...... enterococci and staphylococci.
@ast
In vitro activity of LY333328, ...... enterococci and staphylococci.
@en
prefLabel
In vitro activity of LY333328, ...... enterococci and staphylococci.
@ast
In vitro activity of LY333328, ...... enterococci and staphylococci.
@en
P2093
P2860
P1476
In vitro activity of LY333328, ...... enterococci and staphylococci.
@en
P2093
A C McIntosh
J A Johnson
K M Furness
L Steele-Moore
R J Johnson
R S Schwalbe
W J Holloway
P2860
P304
P407
P577
1996-10-01T00:00:00Z